雖然肺氣腫主要影響肺，它也有全身性的表現。較低的身體質量指數是肺氣腫患者預後 不良的指標。低身體質量指數，低股四頭肌肌肉質量和高發炎生物指標可能存在於肺氣腫。 本研究旨在探討身體質量指數與氣流受限，運動能力或發炎生物指標關聯性。將28例患者評 估身體質量指數，身體及股四頭肌肌肉圍度和力量，氣道阻塞，吸氣容量，運動能力(6 分鐘 步行距離)，氧飽和度，血清炎症標記物(C反應蛋白，腫瘤壞死因子-α 和細胞間素-6) 和生活 品質( 聖喬治呼吸問卷)。身體質量指數與胸圍(R = 0.716，P <0.01), 腹圍(R = 0.783，P <0.01), 股四頭肌周長(R = 0.565，P <0.01) 及上臂周長（R = 0.712，P <0.01)，吸氣容量(R = 0.451，P <0.05)，上臂肌力 (R = 0.490, p <0.01) 及氧飽和度(R = 0.380，P <0.05) 顯著有關。然而，C反 應蛋白(1467±202 微克/ ml) 和細胞間素-6 (8.5±4.2 皮克/ 毫升) 在低身體質量指數(<21 公斤 / 平方米) 的病患相較於高身體質量指數（>21公斤/ 平方米) 的肺氣腫患者，具有較高的C反 應蛋白(911±130 g/ml, p <0.05) 和細胞間素-6 (2.1±0.5 pg/ml, p <0.05)。身體質量指數反映了 肺氣腫患的肢體周長、吸氣容量及發炎生物指標關聯性。

Although emphysema primarily affects the lungs, it also has systemic manifestations. Low body mass index (BMI) is a poor prognostic indicator in patients with emphysema. Low BMI, reduced quadriceps muscle mass and elevated inflammatory biomarker may present in emphysema. This study aims to investigate whether BMI is related to airflow limitation, exercise capacity and inflammatory biomarker. Twenty-eight patients with clinically stable emphysema were evaluated for BMI, circumference of chest, abdomen, quadriceps muscle and upper arm, and right upper arm muscle power, airway obstruction, inspiratory capacity (IC), distance of 6-min walking distance (6MWD), oxygen saturation, and serum inflammatory biomarkers [C-reactive protein (CRP), TNF-α and IL-6]. BMI was significantly associated with circumference of chest (r = 0.716, p <0.01), abdomen(r = 0.783, p <0.01), quadriceps muscle (r = 0.565, p <0.01) and upper arm (r = 0.712, p <0.01), IC (r = 0.451, p <0.05), muscle power of right upper arm (r = 0.490, p <0.01) and oxygen saturation (r = 0.380, p <0.05). However, the levels of CRP (1467 ± 202 μg/ml) and IL-6 (8.5 ± 4.2 pg/ml) in emphysematous patients (n = 10) with lower BMI (<21 kg/m2) were significantly higher than those (CRP (911 ± 130 μg/ml, p <0.05) and IL-6 (2.1 ± 0.5 pg/ml, p <0.05)) of patients (n = 18) with higher BMI (>21 kg/m2). BMI associated circumference of limbs, inspiratory capacity, and inflammatory biomarker in emphysematous patients.